Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
MeSH Number(s)
E02.183.750.500
E02.319.077.500
E02.319.310.037
Concept/Terms
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 36 | 19 | 55 |
1993 | 37 | 33 | 70 |
1994 | 44 | 18 | 62 |
1995 | 42 | 17 | 59 |
1996 | 56 | 23 | 79 |
1997 | 57 | 17 | 74 |
1998 | 71 | 25 | 96 |
1999 | 60 | 31 | 91 |
2000 | 65 | 26 | 91 |
2001 | 63 | 23 | 86 |
2002 | 71 | 32 | 103 |
2003 | 81 | 43 | 124 |
2004 | 90 | 39 | 129 |
2005 | 111 | 42 | 153 |
2006 | 119 | 55 | 174 |
2007 | 110 | 48 | 158 |
2008 | 122 | 63 | 185 |
2009 | 143 | 60 | 203 |
2010 | 160 | 59 | 219 |
2011 | 153 | 73 | 226 |
2012 | 173 | 64 | 237 |
2013 | 177 | 73 | 250 |
2014 | 207 | 103 | 310 |
2015 | 212 | 84 | 296 |
2016 | 185 | 97 | 282 |
2017 | 190 | 97 | 287 |
2018 | 245 | 76 | 321 |
2019 | 278 | 97 | 375 |
2020 | 232 | 131 | 363 |
2021 | 188 | 137 | 325 |
2022 | 13 | 21 | 34 |
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discov. 2022 Apr 01; 12(4):984-1001.
-
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 Apr 01; 28(7):1258-1267.
-
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022 03 10; 386(10):942-950.
-
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 03 08; 114(3):427-435.
-
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 May; 97(5):613-622.
-
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022 Mar; 9(3):e179-e189.
-
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022 Mar; 10(3).
-
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrol Dial Transplant. 2022 02 25; 37(3):507-514.
-
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644.
-
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022 02 24; 139(8):1135-1146.